Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › HORIZON

B-ACTIVE · Training of young scientists in the Biological regulation of the chemokine network to improve treatment of ACTIVE inflammation

HORIZONStatus: SIGNED1 January 202431 December 2027EU funding €2,800,865Call HORIZON-MSCA-2022-DN-01

A number of pharmaceuticals targeting cytokine/chemokine storms in lungs are in development due to an urgent new unmet medical need strengthened by the COVID-19 pandemic. The recent death of > 6.5 million people shows that treating excessive inflammation is still a major problem. Our incomplete understanding of complex immune reactions and resulting doubts on correct drug target identification prohibit efficient drug development and patient treatment. Proper control of inflammation is crucial during infection, wound healing, auto-inflammation, auto-immunity, transplant rejection, etc. Chemokines and their receptors drive leukocyte migration and activation and inflammation. Although the ligands and receptors were identified in the last 3 decades, increasing fundamental, preclinical and sporadic clinical evidence indicates that posttranslational regulation of chemokine ligands and receptors may impact the inflammatory reaction significantly. In this B-ACTIVE network, fundamental and clinical scientists and companies will study the impact of posttranslational modifications of chemokine ligands and receptors and train 10 early stage researchers (ESRs) to future experts in this domain with a translational and interdisciplinary mindset and a network founded already in graduate education. The ESRs will characterize interactions between ligands, receptors and glycosaminoglycans, study signaling pathways and recognize their importance in inflammatory reactions. ESRs will be trained in the complexity of inflammatory responses from basic science to clinical applications and industrial development. B-ACTIVE will improve our understanding of inflammatory reactions, aid in identifying the right drug targets and participate in pharmaceutical development, for better patient treatment with more new active pharmaceutical ingredients being evaluated clinically. The proposed projects are aligned with this overall objective and research strategies of academic and industrial partners.

Consortium · 13 organisations

coordinator

KATHOLIEKE UNIVERSITEIT LEUVEN

BE · €525,240

associatedPartner

GLYCODISPLAY APS

DK

participant

ILYA PHARMA AB

SE · €293,710

participant

ANTAGONIS BIOTHERAPEUTICS GMBH

AT · €270,331

associatedPartner

BECTON DICKINSON BENELUX

BE

associatedPartner

Bacthera Denmark A/S

DK

associatedPartner

Activotec Ltd

UK

participant

KOBENHAVNS UNIVERSITET

DK · €603,576

participant

UPPSALA UNIVERSITET

SE · €293,710

associatedPartner

BRUKER FRANCE SAS

FR

participant

UNIVERSITAET GRAZ

AT · €270,331

participant

UNIVERZITETNI KLINICNI CENTER LJUBLJANA

SI · €242,179

participant

SYNKLINO A/S

DK · €301,788

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.